 BioLife Solutions, Inc. NASDAQ: BLFS BioLife or the Company, a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced the closing of its public offering of 5,951,250 shares of common stock at the public offering price of 14.50 per share, which includes the shares purchased pursuant to the exercise in full of the underwriters option to purchase up to an additional 776,250 shares of its common stock. The gross proceeds from the offering to BioLife, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately 86 million. 